The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Tissue Regenix Group's current ratio for the quarter that ended in Jun. 2025 was 2.88.
Tissue Regenix Group has a current ratio of 2.88. It generally indicates good short-term financial strength.
The historical rank and industry rank for Tissue Regenix Group's Current Ratio or its related term are showing as below:
FRA:LSW'
s Current Ratio Range Over the Past 10 Years
Min: 2.88 Med: 4.77 Max: 42.99
Current: 2.88
During the past 13 years, Tissue Regenix Group's highest Current Ratio was 42.99. The lowest was 2.88. And the median was 4.77.
FRA:LSW's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.885
vs FRA:LSW: 2.88
Tissue Regenix Group (FRA:LSW) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tissue Regenix Group Current Ratio Related Terms
Tissue Regenix Group Current Ratio Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Current Ratio of 2.88 as of Jun. 2025. This is 40% below median its historical median of 4.77. Over the past decade, Tissue Regenix Group's Current Ratio has ranged from 2.88 to 42.99.
Is Tissue Regenix Group's Current Ratio too high?
Tissue Regenix Group's current Current Ratio of 2.88 is 40% below median its 10-year median of 4.77. Over the past 10 years, this metric has ranged from a low of 2.88 to a high of 42.99. The Biotechnology industry median Current Ratio is 3.89. Tissue Regenix Group's value of 2.88 is 25.9% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Current Ratio compare to VRTX and REGN?
Tissue Regenix Group's Current Ratio of 2.88 can be compared against companies in the Biotechnology industry. The industry median Current Ratio is 3.89. Tissue Regenix Group's value of 2.88 is 25.9% below this benchmark. Historically, Tissue Regenix Group's own Current Ratio has ranged from 2.88 to 42.99 over the past decade. While the company's 10-year median is 4.77 vs. the industry median of 3.89, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Current Ratio of 2.88 is 25.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Current Ratio is 2.88, which is 40% below median its own 10-year median of 4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Current Ratio of 2.88. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Current Ratio is 2.88, which is 40% below median its 10-year median of 4.77 and 25.9% below the Biotechnology industry median of 3.89. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Current Ratio is 2.88 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Current Ratio: 2.88 (40% below median its 10-year median of 4.77)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 25.9% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
